LNTH Quote, Financials, Valuation and Earnings

The Cooper Cos., Inc. has a net margin of 7.23% compared to Lantheus Holdings, Inc.'s net margin of 7.94%. Lantheus Holdings, Inc.'s return on equity of 14.66% beat The Cooper Cos., Inc.'s return on equity of 4.56%.

Lantheus Holdings, Inc. has a consensus price target of $84.62, signalling upside risk potential of 14.55%. On the other hand The Cooper Cos., Inc. has an analysts' consensus of $91.00 which suggests that it could grow by 8.24%. Given that Lantheus Holdings, Inc. has higher upside potential than The Cooper Cos., Inc., analysts believe Lantheus Holdings, Inc. is more attractive than The Cooper Cos., Inc..

Lantheus Holdings, Inc. has a beta of -0.076, which suggesting that the stock is 107.602% less volatile than S&P 500. In comparison The Cooper Cos., Inc. has a beta of 1.033, suggesting its more volatile than the S&P 500 by 3.304%.

Lantheus Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Cooper Cos., Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.01 per share. Lantheus Holdings, Inc. pays -- of its earnings as a dividend. The Cooper Cos., Inc. pays out -- of its earnings as a dividend.

Lantheus Holdings, Inc. quarterly revenues are $384M, which are smaller than The Cooper Cos., Inc. quarterly revenues of $1.1B. Lantheus Holdings, Inc.'s net income of $27.8M is lower than The Cooper Cos., Inc.'s net income of $84.6M. Notably, Lantheus Holdings, Inc.'s price-to-earnings ratio is 31.02x while The Cooper Cos., Inc.'s PE ratio is 44.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings, Inc. is 3.37x versus 4.11x for The Cooper Cos., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

ICU Medical, Inc. has a net margin of 7.23% compared to Lantheus Holdings, Inc.'s net margin of -2.91%. Lantheus Holdings, Inc.'s return on equity of 14.66% beat ICU Medical, Inc.'s return on equity of 0.04%.

Lantheus Holdings, Inc. has a consensus price target of $84.62, signalling upside risk potential of 14.55%. On the other hand ICU Medical, Inc. has an analysts' consensus of $182.67 which suggests that it could grow by 16.33%. Given that ICU Medical, Inc. has higher upside potential than Lantheus Holdings, Inc., analysts believe ICU Medical, Inc. is more attractive than Lantheus Holdings, Inc..

Lantheus Holdings, Inc. has a beta of -0.076, which suggesting that the stock is 107.602% less volatile than S&P 500. In comparison ICU Medical, Inc. has a beta of 0.794, suggesting its less volatile than the S&P 500 by 20.551%.

Lantheus Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ICU Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings, Inc. pays -- of its earnings as a dividend. ICU Medical, Inc. pays out -- of its earnings as a dividend.

Lantheus Holdings, Inc. quarterly revenues are $384M, which are smaller than ICU Medical, Inc. quarterly revenues of $540.3M. Lantheus Holdings, Inc.'s net income of $27.8M is higher than ICU Medical, Inc.'s net income of -$15.7M. Notably, Lantheus Holdings, Inc.'s price-to-earnings ratio is 31.02x while ICU Medical, Inc.'s PE ratio is 6,383.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings, Inc. is 3.37x versus 1.74x for ICU Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Iovance Biotherapeutics, Inc. has a net margin of 7.23% compared to Lantheus Holdings, Inc.'s net margin of -135.28%. Lantheus Holdings, Inc.'s return on equity of 14.66% beat Iovance Biotherapeutics, Inc.'s return on equity of -54.43%.

Lantheus Holdings, Inc. has a consensus price target of $84.62, signalling upside risk potential of 14.55%. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $9.11 which suggests that it could grow by 217.46%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Lantheus Holdings, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Lantheus Holdings, Inc..

Lantheus Holdings, Inc. has a beta of -0.076, which suggesting that the stock is 107.602% less volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.765, suggesting its less volatile than the S&P 500 by 23.531%.

Lantheus Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Lantheus Holdings, Inc. quarterly revenues are $384M, which are larger than Iovance Biotherapeutics, Inc. quarterly revenues of $67.5M. Lantheus Holdings, Inc.'s net income of $27.8M is higher than Iovance Biotherapeutics, Inc.'s net income of -$91.3M. Notably, Lantheus Holdings, Inc.'s price-to-earnings ratio is 31.02x while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings, Inc. is 3.37x versus 3.80x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merit Medical Systems, Inc. has a net margin of 7.23% compared to Lantheus Holdings, Inc.'s net margin of 7.22%. Lantheus Holdings, Inc.'s return on equity of 14.66% beat Merit Medical Systems, Inc.'s return on equity of 8.28%.

Lantheus Holdings, Inc. has a consensus price target of $84.62, signalling upside risk potential of 14.55%. On the other hand Merit Medical Systems, Inc. has an analysts' consensus of $103.64 which suggests that it could grow by 26.06%. Given that Merit Medical Systems, Inc. has higher upside potential than Lantheus Holdings, Inc., analysts believe Merit Medical Systems, Inc. is more attractive than Lantheus Holdings, Inc..

Lantheus Holdings, Inc. has a beta of -0.076, which suggesting that the stock is 107.602% less volatile than S&P 500. In comparison Merit Medical Systems, Inc. has a beta of 0.612, suggesting its less volatile than the S&P 500 by 38.827%.

Lantheus Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merit Medical Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings, Inc. pays -- of its earnings as a dividend. Merit Medical Systems, Inc. pays out -- of its earnings as a dividend.

Lantheus Holdings, Inc. quarterly revenues are $384M, which are smaller than Merit Medical Systems, Inc. quarterly revenues of $384.3M. Lantheus Holdings, Inc.'s net income of $27.8M is higher than Merit Medical Systems, Inc.'s net income of $27.8M. Notably, Lantheus Holdings, Inc.'s price-to-earnings ratio is 31.02x while Merit Medical Systems, Inc.'s PE ratio is 42.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings, Inc. is 3.37x versus 3.38x for Merit Medical Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.